Crystal structure of Plasmodium falciparum thioredoxin reductase, a validated drug target.
Plasmodium falciparum is the vector of the most prevalent and deadly form of malaria, and, among the Plasmodium species, it is the one with the highest rate of drug resistance. At the basis of a rational drug design project there is the selection and characterization of suitable target(s). Thioredoxin reductase, the first protection against reactive oxygen species in the erythrocytic phase of the parasite, is essential for its survival. Hence it represents a good target for the design of new anti-malarial active compounds. In this paper we present the first crystal structure of recombinant P. falciparum thioredoxin reductase (PfTrxR) at 2.9Å and discuss its differences with respect to the human orthologue. The most important one resides in the dimer interface, which offers a good binding site for selective non competitive inhibitors. The striking conservation of this feature among the Plasmodium parasites, but not among other Apicomplexa parasites neither in mammals, boosts its exploitability.
Department of Biochemical Sciences and Istituto Pasteur - Fondazione Cenci Bolognetti, Sapienza University of Rome, 00185 Rome, Italy.
Giovanna
G
Boumis
Giorgio
G
Giardina
Francesco
F
Angelucci
Andrea
A
Bellelli
Maurizio
M
Brunori
Daniela
D
Dimastrogiovanni
Fulvio
F
Saccoccia
Adriana E
AE
Miele
D000962:Antimalarials / Q000737:chemistry / Q000494:pharmacology; D018360:Crystallography, X-Ray; D015195:Drug Design; D006801:Humans; D010963:Plasmodium falciparum / Q000201:enzymology*; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D013880:Thioredoxin-Disulfide Reductase / Q000737:chemistry*
D000962:Antimalarials; D013880:Thioredoxin-Disulfide Reductase